Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.57 |
| ▸ | PPARG | P37231 | 8/20 | 0.56 |
| ▸ | PTGES | O14684 | 7/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 7/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29852251 | 0.94 | CTSK (0.52) | CTSKPPARGPTGESALOX5CA2 | |
| SCHEMBL11049297 | 0.93 | CTSK (0.58) | CTSKPPARGPTGESALOX5CA2 | |
| Hydrochloric Acid SCHEMBL5128045 | 0.92 | CTSK (0.57) | CTSKPPARGPTGESALOX5CA2 | |
| SCHEMBL16672761 | 0.91 | CA1 (0.59) | CTSKPPARGPTGESALOX5CA2 | |
| SCHEMBL16672640 | 0.91 | CA1 (0.58) | CTSKPPARGPTGESALOX5CA2 | |
| SCHEMBL19024639 | 0.90 | CTSK (0.56) | CTSKPPARGPTGESALOX5CA2 | |
| SCHEMBL19024668 | 0.88 | CTSK (0.54) | CTSKPPARGPTGESALOX5CA2 | |
| SCHEMBL19024849 | 0.88 | CTSK (0.54) | CTSKPPARGPTGESALOX5CA2 | |
| SCHEMBL19024769 | 0.88 | CTSK (0.54) | CTSKPPARGPTGESALOX5CA2 | |
| SCHEMBL19024708 | 0.88 | CTSK (0.54) | CTSKPPARGPTGESALOX5CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008014505-A2 | BLENDS FOR IMPROVED SOLUBILIZATION OF ACTIVE AND FUNCTIONAL ORGANIC COMPOUNDS | ISP INVESTMENTS INC. (US) | 2008-01-31 | — | — | WO | claimed |
| JP-6108086-A | — | — | None | — | — | JP | disclosed |
| JP-6158088-A | — | — | None | — | — | JP | disclosed |
| EP-2869389-B1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION CELL USING SAME | MITSUBISHI CHEM CORP (JP) | 2019-11-13 | — | — | EP | disclosed |
| US-10320030-B2 | Nonaqueous electrolyte solution and nonaqueous electrolyte battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-06-11 | — | — | US | disclosed |
| US-20150140448-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2869389-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION CELL USING SAME | Mitsubishi Chemical Corporation (JP) | 2015-05-06 | — | — | EP | disclosed |
| US-20140107135-A1 | PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20130136706-A1 | SOLUBILIZING AGENTS FOR ACTIVE OR FUNCTIONAL ORGANIC COMPOUNDS | AQUALON COMPANY | 2013-05-30 | — | — | US | disclosed |
| US-20130136706-A1 | SOLUBILIZING AGENTS FOR ACTIVE OR FUNCTIONAL ORGANIC COMPOUNDS | AQUALON COMPANY | 2013-05-30 | — | — | US | disclosed |
| CN-100528828-C | Production method of racemiation3-hydroxy-3- (2-phenylethyl) hexanoic acid C1-6 alkyl ester | SUMIKA FINE CHEMICALS CO LTD (JP) | 2009-08-19 | — | — | CN | disclosed |
| WO-2008103924-A2 | MEDICATION ADHERENCE MONITORING SYSTEM | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2008-08-28 | — | — | WO | disclosed |
| WO-2007087278-A2 | SOLUBILIZING AGENTS FOR ACTIVE OR FUNCTIONAL ORGANIC COMPOUNDS | ISP INVESTMENTS INC (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20070172437-A1 | Solubilizing agents for active or functional organic compounds | ISP INVESTMENTS INC. | 2007-07-26 | — | — | US | disclosed |
| US-20070172437-A1 | Solubilizing agents for active or functional organic compounds | ISP INVESTMENTS INC. | 2007-07-26 | — | — | US | disclosed |
| CN-1982284-A | Production method of (R) -3 hydroxy-3- (2-phenylethyl) hexanoic acid and intermediate thereof | SUMIKA FINE CHEMICALS CO LTD (JP) | 2007-06-20 | — | — | CN | disclosed |
| CN-1301244-C | Process for producing -3-hydroxy-3- (2-phenylethyl) hexanoic acid and intermediates thereof | SUMITOMO CHEMICAL CO (JP) | 2007-02-21 | — | — | CN | disclosed |
| CN-1617846-A | Process for producing -3-hydroxy-3- (2-phenylethyl) hexanoic acid and intermediates thereof | SUMITOMO CHEMICAL CO (JP) | 2005-05-18 | — | — | CN | disclosed |
| JP-H06158088-A | LOW-ALCOHOL PERFUME COMPOSITION | SHISEIDO CO LTD | 1994-06-07 | — | — | JP | disclosed |
| JP-H06108086-A | LOW-ALCOHOL PERFUME COMPOSITION | SHISEIDO CO LTD | 1994-04-19 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107135-A1 | PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | PLA2G1B, PLA2G4A, PLA2G4B | CTSK 818/4885PPARG 688/4885PTGES 321/4885 |
| US-20130136706-A1 | SOLUBILIZING AGENTS FOR ACTIVE OR FUNCTIONAL ORGANIC COMPOUNDS | CEL, PIGO, ERG28 | CTSK 851/4885PPARG 56/4885PTGES 864/4885 |
| US-20070172437-A1 | Solubilizing agents for active or functional organic compounds | CEL, PIGO, ERG28 | CTSK 851/4885PPARG 56/4885PTGES 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.